Search

Saad B. Omer, M.B.B.S., M.P.H., Ph.D., Founding Dean of the Peter O’Donnell Jr. School of Public Health at UT Southwestern Medical Center, discovered a passion for public health while he was a medical student in Pakistan.

Cooling brain tumor cells to stop them from dividing without killing healthy cells extended the survival of glioblastoma (GBM) animal models dramatically in a study led by a UT Southwestern resident.

Pregnant individuals should be careful regarding energy drinks and their overall intake of caffeine, according to an expert at UT Southwestern Medical Center.

Depression is considered the most common complication of childbirth, and new mothers shouldn’t feel ashamed or embarrassed about seeking mental health care and treatments including therapy and medication, advised experts at UT Southwestern Medical Center.

Ongoing research at UT Southwestern Medical Center exploring the ability of human heart cells to regenerate after a heart attack or other cardiovascular event will be accelerated by a new award from the National Institutes of Health.

Seemingly healthy people whose blood contained antibodies associated with a condition called antiphospholipid syndrome (APS) were significantly more likely to experience a cardiovascular event such as a heart attack or stroke than those without, a study led by UT Southwestern scientists shows.

Despite the convenience of at-home screening tests for early detection of colorectal cancer (CRC), a study led by UT Southwestern Medical Center researchers examining more than a decade of patient data found that about 10% of the tests could not be processed, mostly due to patient error.

Researchers at UT Southwestern Medical Center have developed a novel artificial intelligence (AI) model that analyzes the spatial arrangement of cells in tissue samples.

Two UT Southwestern Medical Center researchers – a biochemist and a molecular biologist – are among 33 distinguished scientists nationwide named Howard Hughes Medical Institute (HHMI) Investigators.

The U.S. Food & Drug Administration has expanded the approved use of belzutifan for treatment of metastatic kidney cancer, another milestone for the novel, first-in-class kidney cancer drug arising from scientific discoveries at UT Southwestern Medical Center.